GlycoScoreDx Overview
- Year Founded
-
2020
- Status
-
Out of Business
- Employees
-
2
- Latest Deal Type
-
Out of Business
- Investors
-
1
GlycoScoreDx General Information
Description
Developer of a cancer blood test intended to detect prostate cancer at an early stage. The company uses a combination of biomarkers to give a clear picture of clinically relevant prostate cancer, which can be adopted by any pathology laboratory and can be performed using existing infrastructure, enabling doctors to ensure that only patients with a clinically significant risk of the disease undergo the invasive procedure of painful prostate-tissue biopsy tests.
Contact Information
Website
www.glycoscoredx.co.ukCorporate Office
- Sandgate House 102 Quayside
- Tyne and Wear
- Newcastle upon Tyne NE1 3DX
- England, United Kingdom
Corporate Office
- Sandgate House 102 Quayside
- Tyne and Wear
- Newcastle upon Tyne NE1 3DX
- England, United Kingdom
GlycoScoreDx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Out of Business | 12-May-2026 | Completed | Out of Business | |||
| 5. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 4. Grant | 01-Apr-2021 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 01-Apr-2021 | Completed | Pre-Clinical Trials | |||
| 2. Grant | 30-Mar-2021 | $499K | Completed | Pre-Clinical Trials | ||
| 1. University Spin-Out | 01-Jan-2020 | Completed | Pre-Clinical Trials |
GlycoScoreDx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| A Ordinary | ||||||||
| Ordinary |
GlycoScoreDx Patents
GlycoScoreDx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020391992-A1 | Prostate cancer biomarkers | Inactive | 29-Nov-2019 | ||
| EP-4065980-A1 | Prostate cancer biomarkers | Inactive | 29-Nov-2019 | ||
| GB-2594103-B | Prostate cancer biomarkers | Active | 29-Nov-2019 | ||
| GB-2595425-B | Prostate cancer biomarkers | Active | 29-Nov-2019 | ||
| US-20230003731-A1 | Prostate cancer biomarkers | Inactive | 29-Nov-2019 | G01N33/57555 |
GlycoScoreDx Signals
GlycoScoreDx Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Newcastle University | University |
GlycoScoreDx FAQs
-
When was GlycoScoreDx founded?
GlycoScoreDx was founded in 2020.
-
Where is GlycoScoreDx headquartered?
GlycoScoreDx is headquartered in Newcastle upon Tyne, United Kingdom.
-
What is the size of GlycoScoreDx?
GlycoScoreDx has 2 total employees.
-
What industry is GlycoScoreDx in?
GlycoScoreDx’s primary industry is Diagnostic Equipment.
-
Is GlycoScoreDx a private or public company?
GlycoScoreDx is a Private company.
-
What is GlycoScoreDx’s current revenue?
The current revenue for GlycoScoreDx is .
-
How much funding has GlycoScoreDx raised over time?
GlycoScoreDx has raised $874K.
-
Who are GlycoScoreDx’s investors?
Newcastle University has invested in GlycoScoreDx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process